L & S Advisors Inc Viking Therapeutics, Inc. Transaction History

L & S Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $609,436 - $771,569	-114,988 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$5.73 - $8.11 $523,280 - $740,629	-91,323 Reduced 44.26%	114,988 $669,000
Q2 2020 Aug 13, 2020	BUY	$4.35 - $8.08 $427,952 - $794,910	98,380 Added 91.15%	206,311 $1.49 Million
Q1 2020 May 13, 2020	SELL	$3.45 - $7.95 $246,944 - $569,045	-71,578 Reduced 39.87%	107,931 $505,000
Q4 2019 Feb 13, 2020	SELL	$6.38 - $8.73 $220,078 - $301,141	-34,495 Reduced 16.12%	179,509 $1.44 Million
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $100,051 - $131,365	15,275 Added 7.69%	214,004 $1.47 Million
Q2 2019 Aug 13, 2019	BUY	$7.67 - $10.63 $214,445 - $297,204	27,959 Added 16.37%	198,729 $1.65 Million
Q1 2019 May 14, 2019	BUY	$7.58 - $9.94 $407,841 - $534,821	53,805 Added 46.0%	170,770 $1.7 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $691,405 - $1.57 Million	-96,565 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $228,240 - $462,364	23,530 Added 32.22%	96,565 $1.68 Million
Q2 2018 Aug 13, 2018	BUY	$3.88 - $12.74 $283,375 - $930,465	73,035 New	73,035 $693,000

466

63.8M

5.76M

3.4M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.6B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on L & S Advisors Inc with notifications on news.